← All compounds · evidence tier first, by design
| Use | E1 | E2 | E3 | E4 | E5 | E6 | E7 | E8 |
|---|---|---|---|---|---|---|---|---|
| E1 Hypoactive sexual desire disorder (HSDD) in premenopausal women | E1 | |||||||
| E3 Erectile dysfunction in men (gray-market claim; not an approved use) | E3 |
Bremelanotide
Cyclic heptapeptide: Ac-Nle-cyclo-(Asp-His-D-Phe-Arg-Trp-Lys-OH), per the US prescribing information. Contains norleucine and a D-amino acid, so no plain one-letter sequence is given. It differs from melanotan II only at the C-terminus (free acid rather than amide).
Non-standard residues or modifications: no plain one-letter sequence
Codes: PT-141 · Brands: Vyleesi
A synthetic cyclic peptide that activates melanocortin receptors. PT-141 is the development code for the same molecule. In the US it is an approved prescription medicine (Vyleesi) for one indication: acquired, generalized hypoactive sexual desire disorder in premenopausal women. No approval was found in the EU, UK, Canada or Australia. Outside that single US indication, material sold as "PT-141" powder is an unapproved product of unverified identity and purity, regardless of the molecule's approved status in the US.
- US A approved
- EU C gray market
- UK C gray market
- CA C gray market
- AU C gray market
- JP ? not verified
- CN ? not verified
01Regulatory status, by jurisdiction
| Jurisdiction | Status | Detail and primary source |
|---|---|---|
| US | Approved | NDA 210557 (Vyleesi autoinjector), approved 21 June 2019; Drugs@FDA lists marketing status Prescription, current applicant Cosette. Approval is limited to premenopausal women with acquired, generalized HSDD; the label states it is not indicated in postmenopausal women, in men, or for improving sexual performance. Bremelanotide sold as research powder is not an FDA-approved product.“VYLEESI is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)”VYLEESI prescribing information (FDA, label revision 10/2020) · retrieved 2026-10-10 |
| EU | Not approved | No entry for bremelanotide in EMA's downloadable table of centrally authorised medicines (retrieved 2026-10-10). National authorisations in individual member states were not checked.“This includes information on marketing authorisations of centrally authorised medicines and post-authorisation procedures.”EMA: Download medicine data · retrieved 2026-10-10 |
| UK | Not approved | A search of the MHRA products database index for 'bremelanotide' returned no authorised product documents.“Scientific reports about marketing authorisations for medicines”MHRA Products · retrieved 2026-10-10 |
| CA | Not approved | The Health Canada Drug Product Database API returns no product with active ingredient bremelanotide (https://health-products.canada.ca/api/drug/activeingredient/?lang=en&type=json&ingredientname=bremelanotide returned an empty list).“The DPD contains product specific information on drugs approved for use in Canada.”Health Canada Drug Product Database (DPD) API Guide · retrieved 2026-10-10 |
| AU | Not approved | The TGA Product and Consumer Medicine Information repository returns no documents for bremelanotide, and bremelanotide is not named in the Poisons Standard (October 2026). Absence of a PI/CMI is strong but not conclusive evidence of no ARTG registration; the ARTG search itself could not be loaded.“Trade Names and Active Ingredients containing bremelanotide . 0 Documents available.”TGA Product and Consumer Medicine Information search · retrieved 2026-10-10 |
| JP CN | Not yet verified from a primary source. No status is shown rather than an unsourced one. | |
Sport (WADA): Not prohibited. Not named on the Prohibited List. As an approved medicine it also falls outside class S0, which covers only substances without current regulatory approval: “Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use” WADA source
02What the human evidence shows
Hypoactive sexual desire disorder (HSDD) in premenopausal women
n/c: not counted here; see the cited review.
Two phase 3 randomised placebo-controlled trials (RECONNECT; 1,267 women randomised in total) found small but statistically significant improvements in a sexual-desire score and reductions in desire-related distress compared with placebo. Nausea, flushing and headache were more frequent than with placebo. A 52-week open-label extension (684 entered, 272 completed) reported no new safety signals. An independent re-analysis of the trial data reported substantially higher adverse-event-related discontinuation on bremelanotide and criticised incomplete reporting of protocol-listed outcomes.
- [1] Two phase 3 RCTs: greater increase in sexual desire score and reduction in related distress than placebo in premenopausal women
- [2] 52-week open-label extension; nausea (40.4%), flushing and headache were the most common treatment-related adverse events
- [3] Independent re-analysis based on FDA application data reporting higher adverse-event discontinuation on bremelanotide and incomplete outcome reporting in the phase 3 publication
Registered-study counts: ClinicalTrials.gov intervention search “bremelanotide”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.
Erectile dysfunction in men (gray-market claim; not an approved use)
n/c: not counted here; see the cited review.
Small randomised studies from the early 2000s tested an intranasal form in men: a phase 1 study in healthy men and men with mild-to-moderate erectile dysfunction reported erectile responses versus placebo, and a second study reported a larger erectile response when combined with sildenafil. A larger RCT in sildenafil non-responders is subject to a 2023 journal Expression of Concern. The approved US label states the product is not indicated in men or for improving sexual performance. No phase 3 evidence in men exists.
- [4] Erectile response greater than placebo in a small phase 1 study; flushing and nausea most common adverse events
- [5] Greater erectile response with combined PT-141 and sildenafil than sildenafil alone in men with erectile dysfunction
- [6] Reported positive responses in sildenafil non-responders; the article is subject to a 2023 Expression of Concern
- [7] Journal of Urology Expression of Concern attached to the 2008 RCT
Registered-study counts: ClinicalTrials.gov intervention search “bremelanotide”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.
Key registered trials
| NCT | Title (as registered) | Phase | Status |
|---|---|---|---|
| NCT02333071 | 1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder | 3 | Completed |
| NCT02338960 | 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder | 3 | Completed |
| NCT06565611 | A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity | 2 | Active, not recruiting |
03Safety signals
There are no adequate human safety data. The absence of reported harm is not evidence of safety.
- Transient increase in blood pressure and decrease in heart rate after each dose [8]
US prescribing information Warnings and Precautions 5.1; contraindicated in uncontrolled hypertension or known cardiovascular disease. Ambulatory monitoring studied in a dedicated trial. - Focal hyperpigmentation (face, gingiva, breasts), not always resolving [9]
US prescribing information Warnings and Precautions; higher risk with darker skin and with daily use. - Nausea, flushing, headache [2]
Most frequent adverse events in phase 3 trials and the open-label extension. - Unknown composition of gray-market PT-141 [9]
No published analytical testing of gray-market material was identified; safety data from the approved product do not transfer to unverified powders. The approved US product is a single-dose autoinjector solution, not a powder.
04What is unknown
- No phase 3 or adequately powered trial in men for any indication
- Efficacy and safety in postmenopausal women are not established
- Long-term cardiovascular effects of repeated transient blood-pressure rises are not characterised beyond 52 weeks
- No published analytical data on the identity, purity, sterility or dose accuracy of gray-market PT-141
- Whether the focal hyperpigmentation seen with frequent use resolves in all cases is not established
05Product quality
No independent purity results have been published for this compound yet. The purity programme will publish full methods and vendor-named results, passes and failures, once its protocol has had legal review.
06Citations
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder (2019). doi:10.1097/aog.0000000000003500
- Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder (2019). doi:10.1097/aog.0000000000003514
- Re-Analyzing Phase III Bremelanotide Trials for “Hypoactive Sexual Desire Disorder” in Women (2021). doi:10.1080/00224499.2021.1885601
- Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction (2004). doi:10.1038/sj.ijir.3901139
- Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response (2005). doi:10.1016/j.urology.2004.10.060
- Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo Controlled Study (2008). doi:10.1016/j.juro.2007.10.063
- Expression of Concern: Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo Controlled Study (2023). doi:10.1097/ju.0000000000003117
- Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. doi:10.1097/hjh.0000000000001221
- VYLEESI (bremelanotide injection), for subcutaneous use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210557s002lbl.pdf
Every DOI is resolved against Crossref and every NCT number against ClinicalTrials.gov, title for title, before publication. Regulatory sources are cited inline above with a verbatim quote and retrieval date.
07Mechanism
Bremelanotide is a non-selective melanocortin receptor agonist; per its US label, binding at MC1R and MC4R is most relevant at therapeutic exposure, MC1R binding increases pigmentation, and the mechanism in HSDD is unknown.
Mechanism is placed last on purpose: a plausible mechanism is not evidence that a compound works in people.
Reviewed by OSMF research team (AI-assisted, source-verified) on 2026-10-10. Found an error? It goes in the corrections log: report it.